Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE

01-10-2007
2. REPORT TYPE 
Annual
DATES COVERED
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER
University of Iowa Iowa City, IA 52242 During the first year of the award we have made substantial progress in achieving the aims of the proposal. I will discuss the progress for each aim of the proposal. (Fig. 3) and that this correlates with proliferation and with movement of ErbB2 to the cell membrane. In the coming year, we will be able to directly test the role of S518 phosphorylation by PKA in regulating ErbB2 trafficking and VS proliferation. BrdU uptake (% ShamIR.control) Sham IR 30 Gy 40 Gy Specific aim 3. Determine whether ErbB2 inhibitors potentiate the ability of radiation therapy (RT) to induce VS apoptosis and reduce proliferation. Following approval to proceed with the use of human tissue we have been able to perform radiation experiments on several cultured human VS specimens. We demonstrate that doses of ≥30 Gy are required to limit VS cell proliferation and that doses ≥40 Gy are required to induce apoptosis (Fig. 4) . Furthermore, we show that inhibition of ErbB2, which reduces VS cell proliferation, protects VS cells against radiation induced cell death. Conversely, activation of ErbB2 by treatment with neuregulin, which promotes VS cell proliferation, increases the radiosensitivity of human VS cells. These results imply that (1) VS are radioresistant relative to most neoplasms, (2) the radiosensitivity of human VS cells depends on proliferative status, and (3) ErbB2 signaling sensitizes VS cells to radiation by promoting proliferation. Thus, we have been able to make substantial progress on the proposed experiments in this aim and are now exploring the possibility that persistent activation of c-Jun N-terminal kinase signaling in protects human VS cells from radiation induced cell death by limiting the accumulation of reactive oxygen species.
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